AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Inclusion Criteria

• •Histologically or cytologically confirmed prostate cancer with a Gleason score available or interpretable and meeting 1 of the following criteria:
• •* No prior chemotherapy and relatively minimal cancer spread
• •* Only one prior taxane-based chemotherapy for aggressive and/or symptomatic disease
• •Must have prostate cancer considered to be hormone refractory or androgen independent by one or more of the following criteria (despite androgen deprivation and anti-androgen withdrawal when applicable):
• •* Progression of unidimensionally measurable disease assessed within 28 days prior to initial administration of drug
• •* Progression of evaluable but not measurable disease assessed within 28 days prior to initial administration of drug for PSA evaluation and within 42 days for imaging studies (e.g., bone scans)
• •Patients must have nonmeasurable disease (e.g., nuclear medicine bone scans) and non-target lesions (e.g., PSA level) assessed within 28 days prior to initial administration of drug
• •* Measurable disease is not required but is allowed
• •Must be surgically or medically castrated
• •* If the method of castration was luteinizing hormone-releasing hormone (LHRH) agonists (e.g., leuprolide or goserelin), then the patient must be willing to continue the use of LHRH agonists
• •* Serum testosterone must be at castrate levels (\< 50 ng/dL) at least 3 months prior to registration
• •ECOG performance status 0-2
• •WBC \>= 3,000/uL
• •Absolute neutrophil count \>= 1,500/uL
• •Platelets \>= 100,000/uL
• •Hemoglobin \> 9 g/d
• •Total bilirubin within normal institutional limits
• •AST/ALT =\< 2.5 x institutional upper limit of normal
• •Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min
• •Must agree to use adequate contraception prior to study entry and for the duration of study participation
• •At least 3 weeks since the completion of chemotherapy and radiotherapy and the patient must have recovered from the side effects of the therapy
• •At least 28 days since prior non-steroidal anti-androgens (e.g., flutamide) (42 days for bicalutamide or nilutamide) or hormonal treatment (e.g., ketoconazole) and demonstrated progression of disease since the agents were suspended
• •Concurrent bisphosphonate therapy is allowed